Two Sigma Advisers LP Trims Position in AtriCure, Inc. (NASDAQ:ATRC)

Two Sigma Advisers LP cut its stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 3.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 639,400 shares of the medical device company's stock after selling 24,700 shares during the period. Two Sigma Advisers LP owned approximately 1.31% of AtriCure worth $19,540,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. increased its stake in shares of AtriCure by 1.8% in the fourth quarter. Blue Trust Inc. now owns 14,751 shares of the medical device company's stock worth $414,000 after buying an additional 265 shares during the last quarter. KBC Group NV raised its holdings in shares of AtriCure by 65.3% in the 4th quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock worth $72,000 after purchasing an additional 932 shares in the last quarter. R Squared Ltd bought a new stake in shares of AtriCure in the 4th quarter worth approximately $89,000. Heck Capital Advisors LLC purchased a new stake in shares of AtriCure in the 4th quarter valued at approximately $60,000. Finally, Calamos Advisors LLC grew its position in AtriCure by 27.9% during the fourth quarter. Calamos Advisors LLC now owns 110,671 shares of the medical device company's stock valued at $3,382,000 after purchasing an additional 24,147 shares in the last quarter. 99.11% of the stock is owned by institutional investors and hedge funds.

AtriCure Trading Up 3.1%

Shares of AtriCure stock traded up $1.02 on Tuesday, hitting $33.73. The stock had a trading volume of 48,871 shares, compared to its average volume of 648,603. The firm has a market capitalization of $1.67 billion, a P/E ratio of -35.50 and a beta of 1.57. The stock has a 50 day moving average of $32.34 and a 200 day moving average of $34.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.11. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. The firm had revenue of $123.62 million for the quarter, compared to analysts' expectations of $122.92 million. During the same period in the prior year, the business earned ($0.28) EPS. The company's revenue for the quarter was up 13.5% compared to the same quarter last year. Sell-side analysts expect that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ATRC has been the subject of several recent research reports. Needham & Company LLC decreased their target price on shares of AtriCure from $51.00 to $44.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. UBS Group dropped their price objective on shares of AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Piper Sandler upped their target price on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Wall Street Zen raised shares of AtriCure from a "hold" rating to a "buy" rating in a report on Saturday. Finally, JPMorgan Chase & Co. decreased their price objective on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a report on Thursday, March 27th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, AtriCure currently has an average rating of "Buy" and a consensus target price of $50.67.

Insider Transactions at AtriCure

In related news, Director Karen Prange sold 6,100 shares of AtriCure stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the completion of the sale, the director now owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This trade represents a 25.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 3.50% of the company's stock.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.